Based on long-standing experience and excellent competence on special fields of immunology and internal medicine, IMTM focuses on the development of new drugs for the treatment of widely distributed and so far insufficiently curable diseases, which are caused and accompanied by immune dysfunction. Our innovative therapeutic concepts are targeted to peptidase-based immunmodulation -  PETIRâ„¢ Drug Design  and thiol-based cytoprotection - ThioTecâ„¢.
Two integrated departments provide a comprehensive set of in silico, in vitro and in vivo methods essential for the discovery, the optimization and the assessment of drug candidates up to clinical trials.

Our scientific and technical staff additionally offers related services for clinical and experimental medicine using latest technologies in molecular and cell biology as well as in experimental interventional medicine.